In a major move, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is acquiring most of 23andMe’s assets for $256 million, including its personal genome service, research services, biobank, and ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, promising to honor existing privacy protections and continue consumer services ...

A federal judge has given the green light for the sale of genetics and biotech company 23andMe.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 4, BMO Capital lifted the price target on the company’s ...

Regeneron Pharmaceuticals said issues at a contract manufacturer have resulted in regulatory setbacks for its Eylea HD eye drug and a proposed lymphoma drug. Regeneron on Friday said an expanded ...

Regeneron Pharmaceuticals REGN will release its quarterly earnings report on Friday, 2025-08-01. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Regeneron ...

(RTTNews) - Regeneron Pharmaceuticals (REGN) announced earnings for second quarter that beat the Street estimates. The company's bottom line totaled $1.392 billion, or $12.81 per share. This ...

Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 13.72% on an annualized basis producing an average annual return of 22.23%. Currently, Regeneron ...

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Friday reported second-quarter earnings of $1.39 billion.

Regeneron (NASDAQ:REGN), a leading biotechnology firm known for its work in immunology and ophthalmology, reported Q2 2025 earnings on August 1, 2025.